insulin is the first cancer drug to target certain genetic defects . Up to 30 per cent of patients with advanced breast cancer have diagnosed with genetic defects - and they responded well to olaparib . Drug prolongs time a patient can live without cancer getting worse .
Olaparib is the first cancer drug to target inherited genetic mutations . Up to 30 per cent of men with advanced prostate cancer have tumours with genetic defects - and they responded well to olaparib . Drug prolongs time a sufferer can live without disease getting worse .